CEO Dominick Colangelo received total compensation of approximately $11.2 million in 2025, which is within a reasonable range for a CEO at a $1.6 billion commercial-stage biotech company delivering 16.5% revenue growth, 33% adjusted EBITDA growth, and second consecutive year of GAAP profitability. Pay mix is strongly performance-oriented: base salary of $860,000 represents less than 8% of total compensation, while equity awards (stock options and restricted stock units together worth roughly $9.4 million at grant) and a performance-based cash bonus ($860,000, paid at 100% of target based on disclosed corporate goal achievement) together make up over 90% of total pay. The incentive structure uses a mix of short-term operational metrics and long-term equity vesting, and the company maintains a meaningful clawback policy adopted in 2023 in compliance with Nasdaq/SEC rules. Prior say-on-pay support has been consistently strong (90–95% over the past three years), indicating shareholders are broadly supportive of the program's structure.

PwC has audited Vericel since 1996, giving it approximately 30 years of tenure, which exceeds the policy's 25-year threshold. However, the non-audit fee ratio is negligible — PwC received only $2,000 in non-audit fees (an annual software license) against $1,640,000 in audit fees, a ratio of roughly 0.1%, far below the 50% concern level. The proxy discloses that the audit committee actively monitors PwC's independence and pre-approves all services. Given the extremely clean fee structure and no evidence of audit failures or restatements, the tenure flag alone does not warrant a no-vote, but shareholders should note the long relationship and the absence of a disclosed rotation plan.